“Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. It’s potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy.
Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases protect sales after generics enter. However in order to achieve this companies must focus increasingly on demonstrating provable benefits, ideally in head to head trials against the original product. This has become necessary as increasingly cost conscious healthcare providers promote the use of generic therapies unless clear advantages are demonstrated.
Biologics increasing dominance of the pharmaceutical market opens new opportunities in reformulation and will drive the sectors future success. Opportunities to deliver less frequent dosing or more convenient and lower cost formulations will continue to drive the development of new technologies.
The report, “Reformulation Strategies – New Technologies Extend Use Beyond Lifecycle Management”, has been written to support companies with their strategic plans to maximize product portfolios and thus increase revenues across the lifecycles of their products. The insights, analysis, and support provided can be used throughout the pharma, biotech, and generics industries.
Please Note: This product is delivered as a zip file
– Introduction to reformulation strategies
– Analysis of the key drivers of reformulation in the pharmaceutical market including coverage of new technologies such as orally disintegrating tablets, anti-tamper technologies and nanotechnology
– Analysis of controlled release reformulation strategies – oral controlled release and injectable controlled release
Key Reasons to Purchase